Invivyd, Inc. (IVVD)

Market Cap	114.20M
Revenue (ttm)	36.69M
Net Income (ttm)	-142.72M
Shares Out	119.96M
EPS (ttm)	-1.19
PE Ratio	n/a
Forward PE	28.36
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,553,169
Open	0.8184
Previous Close	0.8478
Day's Range	0.8100 - 1.0000
52-Week Range	0.3546 - 2.7400
Beta	0.41
Analysts	Strong Buy
Price Target	5.85 (+514.5%)
Earnings Date	May 15, 2025

About IVVD

Invivyd, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company’s pipeline includes PEMGARDA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate, which is in preclinical studies for the prevention or treatment of COVID-19; and Adintrevimab that is in phase 2/3 clinical trials for the prevention and trea...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Aug 6, 2021
• Employees: 100
• Stock Exchange: NASDAQ
• Ticker Symbol: IVVD
• Website: https://invivyd.com

Analyst Forecast

According to 3 analysts, the average rating for IVVD stock is "Strong Buy." The 12-month stock price forecast is $5.85, which is an increase of 514.50% from the latest price.

Price Target

$5.85

(514.50% upside)

Analyst Consensus: Strong Buy